Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry

• DOI: 10.1007/s40123-023-00863-1
• Publication Date: 2024-01-11T15:03:25Z
• Authors: Maria Tarsia; Antonio Vitale; Carla Gaggiano; Jurgen Sota; Anna Maselli; Chiara Bellantonio; Silvana Guerriero; Rosanna Dammacco; Francesco La Torre; Gaafar Ragab; Mohamed Tharwat H...; Alex Fonollosa; Maria Pia Paroli; Emanuela Del Giudice; Maria Cristina Ma...; Marco Cattalini; Lampros Fotis; Giovanni Conti; Angela Mauro; Adele Civino; Federico Diomeda; Alejandra de-la-T...; Carlos Cifuentes-...; Samar Tharwat; José Hernández-Ro...; Verónica Gómez-Ca...; Laura Pelegrín; Kalpana Babu; Vishali Gupta; Francesca Minoia; Piero Ruscitti; Stefania Costi; Luciana Breda; Saverio La Bella; Alessandro Conforti; Maria Antonietta ...; Ester Carreño; Rana Hussein Amin; Salvatore Grosso; Bruno Frediani; Gian Marco Tosi; Alberto Balistreri; Luca Cantarini; Claudia Fabiani
• Keywords: Biosimilars; Pediatric uveitis; Steroid-sparing effect; RE1-994; Adverse events, Biosimilars, Drug retention rate, Pediatric uveitis, Steroid-sparing effect, Tumor necrosis factor (TNF)-inhibitors; Drug retention rate; Ophthalmology; 03 medical and health sciences; Settore MED/38 - Pediatria Generale E Specialistica; 0302 clinical medicine; Adverse events; Adverse events; Biosimilars; Drug retention rate; Pediatric uveitis; Steroid-sparing effect; Tumor necrosis factor (TNF)-inhibitors; Tumor necrosis factor (TNF)-inhibitors; adverse events; biosimilars; drug retention rate; pediatric uveitis; steroid-sparing effect; tumor necrosis factor (TNF)-inhibitors; Original Research

Since many biological drug patents have expired, biosimilar agents (BIOs) been developed; however, there are still some reservations in their use, especially childhood. The aim of the current study is to evaluate efficacy and safety tumor necrosis factor (TNF) inhibitors BIOs as treatment for pediatric non-infectious uveitis (NIU).